Add to ORKGCitation: Finberg JPM. Pharmacology of rasagiline, a new MAO-B inhibitor drug for the treatment of Parkinson's disease wit
Lancet. 2005 Mar 12-18;365(9463):947-54. Rasagiline as an adjunct to levodopa in patients with Park...
The era of MAO-B inhibitors dates back more than 50 years. It began with Kálmán Magyar’s outstanding...
Three inhibitors of type-B monoamine oxidase (MAOB), selegiline, rasagiline, and safinamide, are use...
Julie Leegwater-Kim1, Elena Bortan21Tufts University School of Medicine and Department of Neurology,...
Lakshmi Nayak1, Claire Henchcliffe21Department of Neurology; 2Department of Neurology and Neuroscien...
Item does not contain fulltextRasagiline is a MAO-B inhibitor that is currently registered for the s...
Monoamine oxidase inhibitors (MAO-I) belong to the earliest drugs tried in Parkinson’s disease (PD)....
Rasagiline is a MAO-B inhibitor that is currently registered for the symptomatic treatment of Parkin...
Summary Parkinson's disease (PD) is a therapy area with considerable unmet needs. The current key t...
Parkinson’s Disease (PD) is the second most common neurodegenerative disorder in the world after Alz...
Monoamine oxidase inhibitors (MAO-I) belong to the earliest drugs tried in Parkinson's disease (PD)....
Sprague-Dawley rats received a unilateral injection of 6-hydroxydopamine (6-OHDA) into the striatum ...
Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patie...
The current novel therapeutic approach suggests that multi-targeted compounds, with diverse biologic...
© 2016 Bentham Science Publishers.The pharmacological treatment of Parkinsońs disease (PD) is limite...
Lancet. 2005 Mar 12-18;365(9463):947-54. Rasagiline as an adjunct to levodopa in patients with Park...
The era of MAO-B inhibitors dates back more than 50 years. It began with Kálmán Magyar’s outstanding...
Three inhibitors of type-B monoamine oxidase (MAOB), selegiline, rasagiline, and safinamide, are use...
Julie Leegwater-Kim1, Elena Bortan21Tufts University School of Medicine and Department of Neurology,...
Lakshmi Nayak1, Claire Henchcliffe21Department of Neurology; 2Department of Neurology and Neuroscien...
Item does not contain fulltextRasagiline is a MAO-B inhibitor that is currently registered for the s...
Monoamine oxidase inhibitors (MAO-I) belong to the earliest drugs tried in Parkinson’s disease (PD)....
Rasagiline is a MAO-B inhibitor that is currently registered for the symptomatic treatment of Parkin...
Summary Parkinson's disease (PD) is a therapy area with considerable unmet needs. The current key t...
Parkinson’s Disease (PD) is the second most common neurodegenerative disorder in the world after Alz...
Monoamine oxidase inhibitors (MAO-I) belong to the earliest drugs tried in Parkinson's disease (PD)....
Sprague-Dawley rats received a unilateral injection of 6-hydroxydopamine (6-OHDA) into the striatum ...
Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patie...
The current novel therapeutic approach suggests that multi-targeted compounds, with diverse biologic...
© 2016 Bentham Science Publishers.The pharmacological treatment of Parkinsońs disease (PD) is limite...
Lancet. 2005 Mar 12-18;365(9463):947-54. Rasagiline as an adjunct to levodopa in patients with Park...
The era of MAO-B inhibitors dates back more than 50 years. It began with Kálmán Magyar’s outstanding...
Three inhibitors of type-B monoamine oxidase (MAOB), selegiline, rasagiline, and safinamide, are use...